Hologic stock heads into the open at the merger cash level

At the close on September 10, 2026, Hologic stock was effectively valued at USD 76.00 per share in cash on the Nasdaq as part of a cash-and-stock merger, near a recent 52-week high of USD 76.07. That puts Hologic stock roughly in line with its analyst consensus target of USD 79.13.

Hologic stock closed the last Nasdaq session effectively valued at USD 76.00 per share in cash on September 10, 2026, as set out in the merger consideration, matching the key cash component of the agreed deal terms. The valuation stood very close to a recent 52-week high of USD 76.07, and near an analyst consensus price target of USD 79.13, indicating that the cash element of the transaction is aligned with where the market had recently priced the shares.

September 10, 2026 in numbers

Hologic Inc. (ISIN US4364401012, Nasdaq: HOLX) entered into a cash-and-stock merger structure in which shareholders receive USD 76.00 in cash plus one share of an adjusted HOLX^ security for each existing share, according to the corporate actions overview from Robinhood dated September 10, 2026. Per the same description, the merger consideration was framed around the recent trading band, with the cash leg at USD 76.00 and the stock element providing additional upside exposure tied to the post-merger HOLX^ security. A market wrap on Hologic noted that this USD 76.00 cash component sat just below a recent 52-week high of USD 76.07 and close to the analyst consensus target of USD 79.13, underscoring that the deal terms value the shares near the upper end of their 12-month range, as reported by Ad-hoc-news. Against this backdrop, broader United States equity benchmarks weakened on September 10, 2026, with the S&P 500 falling 44.66 points, or 0.6 percent, to 7,591.70, according to a closing summary from Las Vegas Sun, so Hologic’s effective valuation at the merger cash level came as the wider market moved lower.

Merger terms and today’s focus

The cash-and-stock merger terms remain the central reference point for Hologic today, with investors focused on the USD 76.00 cash per share and the one-for-one allocation of the post-merger HOLX^ security described by Robinhood. In practical terms, this structure crystallizes most of the recent share price gains into cash while leaving a residual equity exposure to the combined entity, which can influence how arbitrage traders and longer-term holders position ahead of today’s United States session. Broader market conditions may also matter for Hologic stock today, as the S&P 500 closed lower on September 10, 2026 and recent commentary has linked that weakness to higher energy prices and profit-taking across large-cap names, as outlined in the index wrap by Las Vegas Sun, which can shape risk appetite across healthcare equities heading into the open.